Implantable Cardioverter-Defibrillators (ICD)

severe right or left ventricular systolic dysfunction Long QT syndrome with documented VT or symptoms suggestive thereof while receiving beta-blocker therapy Short QT interval with sustained VT, or cardiac arrest 3/8 Class of Evidence* Specific Indications Brugada syndrome with type 1 ECG pattern and syncope presumed to be due to VT Catecholaminergic polymorphic ventricular tachycardia (CPVT) with sustained VT or syncope while receiving beta blocker therapy Early repolarization with sustained VT or cardiac arrest Class IIa (Evidence or Opinion In Favor) Idiopathic dilated cardiomyopathy, significant LV dysfunction during optimal medical therapy, and unexplained syncope Cardiomyopathy due to a lamin A/C mutation with unexplained syncope, or an independent indication for a permanent pacemaker, or ≥ 2 high-risk factors (nonsustained VT, intermediate LVEF 35% to 44%, non-missense mutation, male sex) Hypertrophic cardiomyopathy (HCM) with ≥ 1 high risk factors other than sustained VT/VF (family history of premature sudden death, unexplained recent syncope, LV thickness ≥ 30 mm), recent syncope suspected to be arrhythmic in origin, LV apical aneurysm, or LVEF < 50% ARVC without sustained VT/VF or severe right or left ventricular systolic dysfunction but with prior syncope or with multiple other risk factors for ventricular tachyarrhythmias (Towbin JA et al) NYHA
